The ventricular assist device market size has grown rapidly in recent years. It will grow from $2.37 billion in 2025 to $2.69 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to increasing prevalence of end-stage heart failure, limited availability of donor hearts, advancements in mechanical circulatory support technologies, rising clinical acceptance of LVAD therapy, improved surgical outcomes.
The ventricular assist device market size is expected to see rapid growth in the next few years. It will grow to $4.34 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing aging population with cardiac disorders, rising adoption of long-term mechanical support, technological advancements in device durability, expansion of home-based patient monitoring, growing investments in advanced cardiac care infrastructure. Major trends in the forecast period include advancements in miniaturized implantable pump designs, growing adoption of continuous-flow devices, integration of remote patient monitoring capabilities, improved biocompatible materials usage, expansion of destination therapy applications.
Growing awareness of heart failure treatment is anticipated to support the expansion of the ventricular assist device market. Heart failure is a condition in which the heart becomes weakened or stiff, reducing its ability to pump blood efficiently throughout the body. It occurs when the heart cannot supply sufficient blood to meet the body’s needs, with common causes including coronary artery disease, heart attacks, hypertension, and damage to the heart muscle. Increased awareness of available treatment options for heart failure is encouraging broader adoption of ventricular assist devices as a therapeutic solution. For instance, in September 2025, according to the British Heart Foundation, a United Kingdom-based nonprofit organization, the number of people living with cardiovascular disease in the United Kingdom could increase by approximately 1 million by 2030 and by around 2 million by 2040 compared with current levels. As a result, rising awareness of heart failure treatment is expected to drive demand for ventricular assist devices.
Leading companies operating in the ventricular assist device market are prioritizing technological innovations, including laser-welding techniques, to reduce the size and weight of implantable systems while improving biocompatibility and structural strength. The use of precision laser welding enables manufacturers to design smaller and lighter pumps without sacrificing durability, making these devices suitable for a broader patient population and supporting improved long-term clinical outcomes. For example, in March 2024, Evaheart Medical, a China-based artificial heart company, introduced its EVA-Pulsar ventricular assist device, which weighs just 262 grams due to the use of laser-welding technology. The lightweight design closely replicates natural pulse pressure levels of 20-30 millimeters of mercury and supports more physiological cardiac output, helping to reduce risks associated with continuous-flow devices. The EVA-Pulsar has received regulatory approval in Japan, and clinical trials are ongoing in the United States, highlighting its global potential.
In October 2024, Johnson & Johnson, a United States-based healthcare company, completed the acquisition of V Wave Ltd. for an undisclosed consideration. Through this transaction, Johnson & Johnson seeks to strengthen its cardiovascular portfolio by incorporating V Wave’s minimally invasive Ventura Interatrial Shunt, which is designed to reduce elevated left atrial pressure in patients with heart failure with reduced ejection fraction. V Wave Ltd. is an Israel-based medical device company specializing in the development of implantable solutions for heart failure through structural interventional cardiology.
Major companies operating in the ventricular assist device market are Abiomed, Abbott Laboratories, Medtronic, LivaNova PLC, Terumo Corporation, Berlin Heart GmbH, Cirtec, Jarvik Heart Inc., SynCardia Systems LLC, Calon Cardio-Technology Ltd, Huadong Medicine Co. Ltd, Shenzhen Hexin Zondan Medical Equipment Co. Ltd, Sun Medical Technology Research Corp., CorWave SA, CH Biomedical (USA) Inc, Evaheart Inc, BiVACOR Inc, ReliantHeart Inc, Cardiac Assist Inc, Heart Ware International, Braile Biomedica Ltd.
North America was the largest region in the ventricular assist device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ventricular assist device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ventricular assist device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the ventricular assist device market by increasing costs of imported medical-grade metals, precision motors, sensors, electronic control units, and sterilized components used in implantable circulatory systems. North America and Europe are most affected due to reliance on specialized cross-border medical device supply chains, while Asia-Pacific faces cost pressure in advanced device manufacturing. These tariffs are raising production costs and contributing to higher device pricing for hospitals. However, they are also encouraging localized manufacturing, regional supplier development, and greater investment in domestic medical device production capabilities.
The ventricular assist device market research report is one of a series of new reports that provides ventricular assist device market statistics, including ventricular assist device industry global market size, regional shares, competitors with a ventricular assist device market share, detailed ventricular assist device market segments, market trends and opportunities, and any further data you may need to thrive in the ventricular assist device industry. This ventricular assist device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A ventricular assist device (VAD) is an implantable mechanical circulatory device used to treat heart failure by aiding blood circulation throughout the body, supporting vital organ function. The US FDA has approved a diverse range of VADs, offering long-term or permanent assistance for patients with end-stage heart failure.
The primary types of VADs include left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs). LVADs, battery-operated mechanical pumps, help propel blood from the left ventricle to vital organs. They vary in design as transcutaneous or implantable devices and operate with different flow mechanisms such as pulsatile flow and continuous flow. These devices are used for various purposes including bridge-to-transplant (BTT) therapy, destination therapy, bridge-to-recovery (BTR) therapy, and bridge-to-candidacy (BTC) therapy. End-users of VADs include hospitals, ambulatory surgical centers, and cardiology centers.
The ventricular assist device market consists of sales of pulsatile and nonpulsatile LVADs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The ventricular assist device market size is expected to see rapid growth in the next few years. It will grow to $4.34 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing aging population with cardiac disorders, rising adoption of long-term mechanical support, technological advancements in device durability, expansion of home-based patient monitoring, growing investments in advanced cardiac care infrastructure. Major trends in the forecast period include advancements in miniaturized implantable pump designs, growing adoption of continuous-flow devices, integration of remote patient monitoring capabilities, improved biocompatible materials usage, expansion of destination therapy applications.
Growing awareness of heart failure treatment is anticipated to support the expansion of the ventricular assist device market. Heart failure is a condition in which the heart becomes weakened or stiff, reducing its ability to pump blood efficiently throughout the body. It occurs when the heart cannot supply sufficient blood to meet the body’s needs, with common causes including coronary artery disease, heart attacks, hypertension, and damage to the heart muscle. Increased awareness of available treatment options for heart failure is encouraging broader adoption of ventricular assist devices as a therapeutic solution. For instance, in September 2025, according to the British Heart Foundation, a United Kingdom-based nonprofit organization, the number of people living with cardiovascular disease in the United Kingdom could increase by approximately 1 million by 2030 and by around 2 million by 2040 compared with current levels. As a result, rising awareness of heart failure treatment is expected to drive demand for ventricular assist devices.
Leading companies operating in the ventricular assist device market are prioritizing technological innovations, including laser-welding techniques, to reduce the size and weight of implantable systems while improving biocompatibility and structural strength. The use of precision laser welding enables manufacturers to design smaller and lighter pumps without sacrificing durability, making these devices suitable for a broader patient population and supporting improved long-term clinical outcomes. For example, in March 2024, Evaheart Medical, a China-based artificial heart company, introduced its EVA-Pulsar ventricular assist device, which weighs just 262 grams due to the use of laser-welding technology. The lightweight design closely replicates natural pulse pressure levels of 20-30 millimeters of mercury and supports more physiological cardiac output, helping to reduce risks associated with continuous-flow devices. The EVA-Pulsar has received regulatory approval in Japan, and clinical trials are ongoing in the United States, highlighting its global potential.
In October 2024, Johnson & Johnson, a United States-based healthcare company, completed the acquisition of V Wave Ltd. for an undisclosed consideration. Through this transaction, Johnson & Johnson seeks to strengthen its cardiovascular portfolio by incorporating V Wave’s minimally invasive Ventura Interatrial Shunt, which is designed to reduce elevated left atrial pressure in patients with heart failure with reduced ejection fraction. V Wave Ltd. is an Israel-based medical device company specializing in the development of implantable solutions for heart failure through structural interventional cardiology.
Major companies operating in the ventricular assist device market are Abiomed, Abbott Laboratories, Medtronic, LivaNova PLC, Terumo Corporation, Berlin Heart GmbH, Cirtec, Jarvik Heart Inc., SynCardia Systems LLC, Calon Cardio-Technology Ltd, Huadong Medicine Co. Ltd, Shenzhen Hexin Zondan Medical Equipment Co. Ltd, Sun Medical Technology Research Corp., CorWave SA, CH Biomedical (USA) Inc, Evaheart Inc, BiVACOR Inc, ReliantHeart Inc, Cardiac Assist Inc, Heart Ware International, Braile Biomedica Ltd.
North America was the largest region in the ventricular assist device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ventricular assist device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ventricular assist device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the ventricular assist device market by increasing costs of imported medical-grade metals, precision motors, sensors, electronic control units, and sterilized components used in implantable circulatory systems. North America and Europe are most affected due to reliance on specialized cross-border medical device supply chains, while Asia-Pacific faces cost pressure in advanced device manufacturing. These tariffs are raising production costs and contributing to higher device pricing for hospitals. However, they are also encouraging localized manufacturing, regional supplier development, and greater investment in domestic medical device production capabilities.
The ventricular assist device market research report is one of a series of new reports that provides ventricular assist device market statistics, including ventricular assist device industry global market size, regional shares, competitors with a ventricular assist device market share, detailed ventricular assist device market segments, market trends and opportunities, and any further data you may need to thrive in the ventricular assist device industry. This ventricular assist device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A ventricular assist device (VAD) is an implantable mechanical circulatory device used to treat heart failure by aiding blood circulation throughout the body, supporting vital organ function. The US FDA has approved a diverse range of VADs, offering long-term or permanent assistance for patients with end-stage heart failure.
The primary types of VADs include left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs). LVADs, battery-operated mechanical pumps, help propel blood from the left ventricle to vital organs. They vary in design as transcutaneous or implantable devices and operate with different flow mechanisms such as pulsatile flow and continuous flow. These devices are used for various purposes including bridge-to-transplant (BTT) therapy, destination therapy, bridge-to-recovery (BTR) therapy, and bridge-to-candidacy (BTC) therapy. End-users of VADs include hospitals, ambulatory surgical centers, and cardiology centers.
The ventricular assist device market consists of sales of pulsatile and nonpulsatile LVADs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Ventricular Assist Device Market Characteristics
3. Ventricular Assist Device Market Supply Chain Analysis
4. Global Ventricular Assist Device Market Trends and Strategies
5. Ventricular Assist Device Market Analysis of End Use Industries
7. Global Ventricular Assist Device Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Ventricular Assist Device Total Addressable Market (TAM) Analysis for the Market
9. Ventricular Assist Device Market Segmentation
10. Ventricular Assist Device Market Regional and Country Analysis
11. Asia-Pacific Ventricular Assist Device Market
12. China Ventricular Assist Device Market
13. India Ventricular Assist Device Market
14. Japan Ventricular Assist Device Market
15. Australia Ventricular Assist Device Market
16. Indonesia Ventricular Assist Device Market
17. South Korea Ventricular Assist Device Market
18. Taiwan Ventricular Assist Device Market
19. South East Asia Ventricular Assist Device Market
20. Western Europe Ventricular Assist Device Market
21. UK Ventricular Assist Device Market
22. Germany Ventricular Assist Device Market
23. France Ventricular Assist Device Market
24. Italy Ventricular Assist Device Market
25. Spain Ventricular Assist Device Market
26. Eastern Europe Ventricular Assist Device Market
27. Russia Ventricular Assist Device Market
28. North America Ventricular Assist Device Market
29. USA Ventricular Assist Device Market
30. Canada Ventricular Assist Device Market
31. South America Ventricular Assist Device Market
32. Brazil Ventricular Assist Device Market
33. Middle East Ventricular Assist Device Market
34. Africa Ventricular Assist Device Market
36. Ventricular Assist Device Market Competitive Landscape and Company Profiles
37. Ventricular Assist Device Market Other Major and Innovative Companies
40. Ventricular Assist Device Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Ventricular Assist Device Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses ventricular assist device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ventricular assist device? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ventricular assist device market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Left Ventricular Assist Devices (LVADs); Right Ventricular Assist Devices (RVADs); Biventricular Assist Devices (BIVADs)2) By Flow Mechanism: Pulsatile Flow; Continuous Flow
3) By Design: Transcutaneous Ventricular Assist Devices; Implantable Ventricular Assist Devices
4) By Application: Bridge-To-Transplant (BTT) Therapy; Destination Therapy; Bridge-To-Recovery (BTR) Therapy; Bridge-To-Candidacy (BTC) Therapy
5) By End Users: Hospital; Ambulatory Surgical Centres; Cardiology Centres
Subsegments:
1) By Left Ventricular Assist Devices (LVADs): Implantable LVADs; Temporary LVADs2) By Right Ventricular Assist Devices (RVADs): Implantable RVADs; Temporary RVADs
3) By Biventricular Assist Devices (BIVADs): Full Support BIVADs; Hybrid BIVADs
Companies Mentioned: Abiomed; Abbott Laboratories; Medtronic; LivaNova PLC; Terumo Corporation; Berlin Heart GmbH; Cirtec; Jarvik Heart Inc.; SynCardia Systems LLC; Calon Cardio-Technology Ltd; Huadong Medicine Co. Ltd; Shenzhen Hexin Zondan Medical Equipment Co. Ltd; Sun Medical Technology Research Corp.; CorWave SA; CH Biomedical (USA) Inc; Evaheart Inc; BiVACOR Inc; ReliantHeart Inc; Cardiac Assist Inc; Heart Ware International; Braile Biomedica Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Ventricular Assist Device market report include:- Abiomed
- Abbott Laboratories
- Medtronic
- LivaNova PLC
- Terumo Corporation
- Berlin Heart GmbH
- Cirtec
- Jarvik Heart Inc.
- SynCardia Systems LLC
- Calon Cardio-Technology Ltd
- Huadong Medicine Co. Ltd
- Shenzhen Hexin Zondan Medical Equipment Co. Ltd
- Sun Medical Technology Research Corp.
- CorWave SA
- CH Biomedical (USA) Inc
- Evaheart Inc
- BiVACOR Inc
- ReliantHeart Inc
- Cardiac Assist Inc
- Heart Ware International
- Braile Biomedica Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.69 Billion |
| Forecasted Market Value ( USD | $ 4.34 Billion |
| Compound Annual Growth Rate | 12.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
